Raman Sood
Research Subjects
Research Interests
Raman Sood has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Harry Carloss
Western Kentucky Hematology/Oncology Group, Paducah, Kentucky
1 shared publicationIan B. Walters
Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts
1 shared publicationJose Lopez
Cancer Care Centers of South Texas, Fredericksburg, Texas
1 shared publicationMark Druck
Combined Hematology Oncology Practice of New Jersey, Jersey City, New Jersey
1 shared publicationMartin Lee
Park Nicollet Cancer Center, St Louis Park, Minnesota
1 shared publicationRobert Kerr
Southwest Regional Cancer Center, Austin, Texas
1 shared publication
Latest Publications
- Open Access
- 30 July 2009
- Published by Wiley in American Journal of Hematology
- Vol. 84 (10) , 657-660
Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib
This clinical trial was conducted to determine the safety and efficacy of bortezomib retreatment in patients with multiple myeloma (MM) who had previously responded to bortezomib. Patients with progressive MM who had previously tolerated bortezomib as a single agent or in combination with other drugs, with a minimum of partial response (PR; ≥50% M‐protein reduction) for ≥4 months, who had not received intervening MM therapy, were retreated with bortezomib (days 1, 4, 8, and 11 of a 21‐day cycle) with a starting dose being the dose at which the patient ended the initial treatment. Patients were allowed to receive bortezomib on retreatment in combination with dexamethasone, thalidomide, or doxorubicin. Thirty‐two patients received bortezomib retreatment (most with added dexamethasone). The median treatment‐free interval (last dose of initial bortezomib treatment to first dose of retreatment) was 9.9 (range 2.5–34.0) months. The median duration of retreatment was 2.8 (<1–7.9) months; median total duration of bortezomib treatment was 6.7 (2.5–19.8) months. Based on the investigators' assessment of best response, the overall response rate (complete plus PR) was 50%. The median time from start of retreatment to progressive disease (PD) was 6.6 (95% confidence interval: 5.1–9.6) months. Thirteen patients (41%) experienced PN; bortezomib‐related SAEs were reported in four patients. Retreatment with bortezomib alone or in combination is effective and well tolerated in patients with MM who have responded to their initial bortezomib treatment. Am. J. Hematol., 2009.
- 30 July 2009
- Published by Wiley in American Journal of Hematology
- Vol. 84 (10) , 657-660
Open AccessRetreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib
This clinical trial was conducted to determine the safety and efficacy of bortezomib retreatment in patients with multiple myeloma (MM) who had previously responded to bortezomib. Patients with progressive MM who had previously tolerated bortezomib as a single agent or in combination with other drugs, with a minimum of partial response (PR; ≥50% M‐protein reduction) for ≥4 months, who had not received intervening MM therapy, were retreated with bortezomib (days 1, 4, 8, and 11 of a 21‐day cycle) with a starting dose being the dose at which the patient ended the initial treatment. Patients were allowed to receive bortezomib on retreatment in combination with dexamethasone, thalidomide, or doxorubicin. Thirty‐two patients received bortezomib retreatment (most with added dexamethasone). The median treatment‐free interval (last dose of initial bortezomib treatment to first dose of retreatment) was 9.9 (range 2.5–34.0) months. The median duration of retreatment was 2.8 (<1–7.9) months; median total duration of bortezomib treatment was 6.7 (2.5–19.8) months. Based on the investigators' assessment of best response, the overall response rate (complete plus PR) was 50%. The median time from start of retreatment to progressive disease (PD) was 6.6 (95% confidence interval: 5.1–9.6) months. Thirteen patients (41%) experienced PN; bortezomib‐related SAEs were reported in four patients. Retreatment with bortezomib alone or in combination is effective and well tolerated in patients with MM who have responded to their initial bortezomib treatment. Am. J. Hematol., 2009.